Varlilumab
- Generic Name
- Varlilumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1393344-72-3
- Unique Ingredient Identifier
- 0125DUV5XC
- Background
Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
- Conditions
- Metastatic Distal Bile Duct AdenocarcinomaUnresectable Liver CarcinomaMetastatic Gallbladder CarcinomaRecurrent Distal Bile Duct AdenocarcinomaMetastatic Intrahepatic CholangiocarcinomaRecurrent Gallbladder CarcinomaRecurrent Intrahepatic CholangiocarcinomaStage IV Distal Bile Duct Cancer AJCC v8Stage IV Gallbladder Cancer AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT04941287
- Locations
- ๐บ๐ธ
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
๐บ๐ธEmory Saint Joseph's Hospital, Atlanta, Georgia, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 26
- Registration Number
- NCT03307746
- Locations
- ๐ฌ๐ง
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
๐ฌ๐งThe Christie NHS Foundation Trust, Manchester, United Kingdom
๐ฌ๐งPlymouth Hospitals NHS Trust, Plymouth, United Kingdom
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Effusion LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory T-Cell/Histiocyte-Rich Large B-Cell LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Mucocutaneous Ulcer
- Interventions
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT03038672
- Locations
- ๐บ๐ธ
HaysMed, Hays, Kansas, United States
๐บ๐ธUniversity Health Truman Medical Center, Kansas City, Missouri, United States
๐บ๐ธMayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.